# A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

> **NCT07206225** · PHASE1 · RECRUITING · sponsor: **Pfizer** · enrollment: 294 (estimated)

## Conditions studied

- Non-muscle Invasive Bladder Cancer

## Interventions

- **DRUG:** PF-08052667
- **DRUG:** Sasanlimab
- **DRUG:** BCG
- **DRUG:** PF-02921367

## Key facts

- **NCT ID:** NCT07206225
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-06
- **Primary completion:** 2030-01-29
- **Final completion:** 2033-01-28
- **Target enrollment:** 294 (ESTIMATED)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07206225

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07206225, "A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07206225. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*